Published in Neurobiol Aging on December 28, 2004
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol (2013) 4.16
Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med (2011) 3.28
Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A (2005) 2.45
Endoplasmic reticulum stress is important for the manifestations of α-synucleinopathy in vivo. J Neurosci (2012) 2.35
Neuropathologic substrates of Parkinson disease dementia. Ann Neurol (2012) 2.10
Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain (2011) 2.02
Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS One (2008) 1.84
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat Rev Neurosci (2013) 1.82
Interleukin-1 mediates Alzheimer and Lewy body pathologies. J Neuroinflammation (2006) 1.47
Amyloid imaging of Lewy body-associated disorders. Mov Disord (2010) 1.27
Recent advances in our understanding of neurodegeneration. J Neural Transm (Vienna) (2009) 1.27
CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain (2006) 1.25
Inflammation in the early stages of neurodegenerative pathology. J Neuroimmunol (2011) 1.21
The neurobiological basis of cognitive impairment in Parkinson's disease. Mov Disord (2014) 1.17
Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2. Hum Mol Genet (2012) 1.10
An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology. J Neurol Neurosurg Psychiatry (2012) 1.09
Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med (2012) 1.06
Role of synucleins in Alzheimer's disease. Neurotox Res (2009) 0.98
Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. Hum Mol Genet (2014) 0.94
Interaction between α-synuclein and other proteins in neurodegenerative disorders. ScientificWorldJournal (2011) 0.89
Amyloid PET imaging: applications beyond Alzheimer's disease. Clin Transl Imaging (2015) 0.88
Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease. Neurobiol Aging (2014) 0.88
The significance of α-synuclein, amyloid-β and tau pathologies in Parkinson's disease progression and related dementia. Neurodegener Dis (2013) 0.88
Tauopathies and synucleinopathies: do cerebrospinal fluid beta-amyloid peptides reflect disease-specific pathogenesis? J Neural Transm (Vienna) (2007) 0.87
Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson's disease. Alzheimers Res Ther (2014) 0.86
Fractalkine Mediates Communication between Pathogenic Proteins and Microglia: Implications of Anti-Inflammatory Treatments in Different Stages of Neurodegenerative Diseases. Int J Alzheimers Dis (2012) 0.85
Wild type and P301L mutant Tau promote neuro-inflammation and α-Synuclein accumulation in lentiviral gene delivery models. Mol Cell Neurosci (2011) 0.85
Protein Transmission, Seeding and Degradation: Key Steps for α-Synuclein Prion-Like Propagation. Exp Neurobiol (2014) 0.84
α-Synuclein as CSF and Blood Biomarker of Dementia with Lewy Bodies. Int J Alzheimers Dis (2012) 0.83
Abnormal neurites containing C-terminally truncated alpha-synuclein are present in Alzheimer's disease without conventional Lewy body pathology. Am J Pathol (2010) 0.83
Presence of cerebral amyloid modulates phenotype and pattern of neurodegeneration in early Parkinson's disease. J Neurol Neurosurg Psychiatry (2016) 0.82
Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5--implications for dementia with Lewy bodies. Mol Neurodegener (2014) 0.82
Cerebral amyloid angiopathy in Lewy body disease. J Neural Transm (Vienna) (2008) 0.81
CSF beta-amyloid 1-42 - what are we measuring in Alzheimer's disease? Ann Clin Transl Neurol (2014) 0.80
Familial dementia with frontotemporal features associated with M146V presenilin-1 mutation. Brain Pathol (2013) 0.78
From model system to clinical medicine: pathophysiologic links of common proteinopathies. Alzheimers Res Ther (2010) 0.76
Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis. Eur J Nucl Med Mol Imaging (2015) 0.76
Comparing Cerebral White Matter Lesion Burdens between Parkinson's Disease with and without Dementia. J Mov Disord (2010) 0.76
The Relationship between Parkin and Protein Aggregation in Neurodegenerative Diseases. Front Psychiatry (2010) 0.76
α-Synuclein increases β-amyloid secretion by promoting β-/γ-secretase processing of APP. PLoS One (2017) 0.75
Decrease in Aβ42 predicts dopa-resistant gait progression in early Parkinson disease. Neurology (2017) 0.75
Abnormal metabolic brain network associated with Parkinson's disease: replication on a new European sample. Neuroradiology (2017) 0.75
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science (2002) 8.41
PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci U S A (2009) 8.25
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A (2005) 6.98
Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci (2005) 5.93
Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet (2003) 5.92
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci (2006) 5.32
Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet (2007) 4.99
S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science (2004) 4.97
Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron (2010) 4.76
The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS (2005) 4.48
Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med (2010) 4.45
PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease. Cell (2011) 4.00
Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci (2005) 3.92
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol (2006) 3.72
Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 3.61
Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci U S A (2006) 3.47
Poly(ADP-ribose) (PAR) polymer is a death signal. Proc Natl Acad Sci U S A (2006) 3.41
Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A (2002) 3.33
Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron (2009) 3.15
CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet (2004) 3.12
Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A (2005) 3.00
DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci U S A (2007) 2.87
Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest (2006) 2.86
Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci (2006) 2.85
A hierarchical NGF signaling cascade controls Ret-dependent and Ret-independent events during development of nonpeptidergic DRG neurons. Neuron (2007) 2.83
Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum Mol Genet (2005) 2.72
Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes. Nucleic Acids Res (2008) 2.70
Impact of Alzheimer's pathology on cognitive trajectories in nondemented elderly. Ann Neurol (2006) 2.68
Repeat expansion in C9ORF72 in Alzheimer's disease. N Engl J Med (2012) 2.58
Nitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis. Nat Cell Biol (2008) 2.56
Psychopathology in patients with degenerative cerebellar diseases: a comparison to Huntington's disease. Am J Psychiatry (2002) 2.52
Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J Neurosci (2009) 2.47
Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. J Cell Biol (2002) 2.47
Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A (2005) 2.45
Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. Hum Mol Genet (2007) 2.44
Endoplasmic reticulum stress is important for the manifestations of α-synucleinopathy in vivo. J Neurosci (2012) 2.35
Hippocampal neurons in pre-clinical Alzheimer's disease. Neurobiol Aging (2004) 2.31
RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc Natl Acad Sci U S A (2013) 2.31
Recent advances in the genetics of Parkinson's disease. Annu Rev Genomics Hum Genet (2011) 2.29
Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord (2008) 2.28
Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol (2006) 2.27
Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J Biol Chem (2003) 2.26
A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. Clin Infect Dis (2005) 2.25
Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp Neurol (2009) 2.24
Impact of nonoperative treatment, vertebroplasty, and kyphoplasty on survival and morbidity after vertebral compression fracture in the medicare population. J Bone Joint Surg Am (2013) 2.24
Understanding microRNAs in neurodegeneration. Nat Rev Neurosci (2009) 2.22
Neuropsychiatric symptoms in Parkinson's disease. Mov Disord (2009) 2.20
Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol (2012) 2.20
Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality. Proc Natl Acad Sci U S A (2004) 2.20
Apoptosis-inducing factor substitutes for caspase executioners in NMDA-triggered excitotoxic neuronal death. J Neurosci (2004) 2.17
Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin. Hum Mol Genet (2005) 2.11
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J Neurosci (2005) 2.06
Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum Mol Genet (2004) 2.02
Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc Natl Acad Sci U S A (2004) 1.99
Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med (2012) 1.99
Parkin-mediated lysine 63-linked polyubiquitination: a link to protein inclusions formation in Parkinson's and other conformational diseases? Neurobiol Aging (2005) 1.96
Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo. J Neurosci (2012) 1.95
Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol Sci (2004) 1.95
Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One (2011) 1.93
Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum Mol Genet (2005) 1.92
The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci (2008) 1.86
A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization. J Neurochem (2003) 1.82
Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function. Proc Natl Acad Sci U S A (2010) 1.81
Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents. J Biol Chem (2007) 1.80
Role of nitric oxide in Parkinson's disease. Pharmacol Ther (2005) 1.77
PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury. J Neurochem (2004) 1.76
Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J Neurosci (2005) 1.75
A nitric oxide signaling pathway controls CREB-mediated gene expression in neurons. Mol Cell (2006) 1.75
Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol (2005) 1.74
Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda. BMC Psychiatry (2010) 1.73
Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos). Sci Signal (2011) 1.73
Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Mov Disord (2008) 1.71
Psychosocial risk factors of HIV morbidity and mortality: findings from the Multicenter AIDS Cohort Study (MACS). J Clin Exp Neuropsychol (2003) 1.70
Poly(ADP-ribose) polymerase-1 and apoptosis inducing factor in neurotoxicity. Neurobiol Dis (2003) 1.69
Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci U S A (2006) 1.66
What causes cell death in Parkinson's disease? Ann Neurol (2008) 1.66
Valproic acid prevents brain injury in a canine model of hypothermic circulatory arrest: a promising new approach to neuroprotection during cardiac surgery. Ann Thorac Surg (2006) 1.64
HIV subtype D is associated with dementia, compared with subtype A, in immunosuppressed individuals at risk of cognitive impairment in Kampala, Uganda. Clin Infect Dis (2009) 1.64
CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity. Proc Natl Acad Sci U S A (2009) 1.64